Landos Biopharma, Inc. (LABP): Price and Financial Metrics

Landos Biopharma, Inc. (LABP): $3.84

0.01 (-0.26%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add LABP to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#199 of 443

in industry

LABP Price/Volume Stats

Current price $3.84 52-week high $7.57
Prev. close $3.85 52-week low $2.11
Day low $3.53 Volume 8,405
Day high $3.88 Avg. volume 23,777
50-day MA $3.88 Dividend yield N/A
200-day MA $3.58 Market Cap 11.97M

LABP Stock Price Chart Interactive Chart >


Landos Biopharma, Inc. (LABP) Company Bio


Landos Biopharma, Inc. operates as a pharmaceutical company. The Company discovers and develops oral therapeutics for patients with autoimmune diseases. Landos Biopharma serves customers worldwide.


LABP Latest News Stream


Event/Time News Detail
Loading, please wait...

LABP Latest Social Stream


Loading social stream, please wait...

View Full LABP Social Stream

Latest LABP News From Around the Web

Below are the latest news stories about LANDOS BIOPHARMA INC that investors may wish to consider to help them evaluate LABP as an investment opportunity.

Landos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 Congress

NX-13 Demonstrated Rapid Symptomatic Relief and Improvement in Multiple Biomarkers that Correlated With Early Endoscopic Response in Patients With Ulcerative Colitis (UC) NEXUS Phase 2 Clinical Trial is Ongoing; Top-line Readout Expected in Q4 2024 NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced presentation of new data on the rapi

Yahoo | September 19, 2023

Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells

Collaboration Will Focus on Defining the Effects Of NX-13 in Ulcerative Colitis Patient Derived Organoid ModelsNEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a strategic research collaboration to investigate the effects of NX-13 on epithelial cells with the Inflammatory Bowel Disease (IBD) Team at KU Leuven and University Hospital

Yahoo | September 14, 2023

Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results

Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the second quarter ended June

Yahoo | August 9, 2023

Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will participate at the Jefferies Healthcare Conference, to be held from June 7-9, 2023 in New York, NY. Gregory Oakes, Chief Executive Officer, and Fabio Cataldi, Chief Medical Officer, will provide a corporate update, including highlights of the NX-13 program and the recent la

Yahoo | May 31, 2023

Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee. “Dr. Batycky is an accomplished biopharmaceutical executive and an important addition to Landos’ Board,” said Gregory Oakes, President and CEO of Landos. “Dr. Batycky has a proven track record, and we

Yahoo | May 30, 2023

Read More 'LABP' Stories Here

LABP Price Returns

1-mo 3.50%
3-mo 11.47%
6-mo 37.00%
1-year -42.97%
3-year N/A
5-year N/A
YTD -23.22%
2022 -89.58%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!